Source: Healio, April 2017

He focused his discussion of the most effective treatment options around a case presentation of a 52-year-old man with BRAF wild-type esophageal melanoma.

Factors that may affect an oncologist’s decision between single-agent PD-1 therapy and combination therapy include comorbidities, contraindications to steroids or immunosuppression, pace and disease burden, and patient communications with health care providers.